Regulus Therapeutics Inc. - Common Stock (RGLS)

Competitors to Regulus Therapeutics Inc. - Common Stock (RGLS)

Alnylam Pharmaceuticals, Inc. 

Alnylam Pharmaceuticals is a leader in the development of RNAi therapeutics and has successfully launched several products. The company's established presence and extensive clinical experience in RNAi provide significant competition for Regulus Therapeutics, which is also working on RNA-based treatments. While Regulus focuses more on microRNAs, Alnylam's diverse pipeline and successful commercialization of RNAi therapies give it a strong market position, making them the leader in this sector.

Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals specializes in RNA interference (RNAi) technologies to develop therapies for rare diseases. Like Regulus, Dicerna also works with RNA-targeted drugs, but their unique approach using proprietary GalXC technology distinguishes their pipeline in the RNA therapeutics field. Dicerna's advancements in delivering RNAi therapeutics provide them with a competitive edge, particularly in terms of drug delivery systems and efficacy in target tissues, making them a formidable competitor.

Intellia Therapeutics, Inc. 

Intellia Therapeutics utilizes CRISPR/Cas9 technology for gene editing, which overlaps with the interests of Regulus Therapeutics, particularly in genetic disorders and oncology. While Intellia emphasizes gene therapy, both companies operate in the expansive field of genetic medicine, creating a competitive landscape. Regulus may have a more specialized focus on microRNA therapies, but Intellia's broader applications and cutting-edge approach to gene editing give it a competitive advantage in the market.

Mirna Therapeutics, Inc.

Mirna Therapeutics focuses on the development of microRNA-based therapies, similar to Regulus Therapeutics. Both companies aim to leverage microRNA science for innovative treatments, particularly in areas such as oncology. While Regulus has a well-established portfolio with multiple partnerships and collaborations, Mirna's specific focus on solid tumors and proven clinical candidates provides it a unique niche, thereby creating a competitive environment where both companies are vying for the same therapeutic targets, though Regulus is perceived to have a broader pipeline.

Scribe Therapeutics, Inc.

Scribe Therapeutics focuses on engineered CRISPR-based therapeutics, which positions it within the same evolutionary biology and genetic medicine arena as Regulus Therapeutics. While Regulus is working towards microRNA therapies, Scribe's focus on innovative CRISPR technology may affect Regulus's pipeline by providing alternative gene-editing pathways for similar diseases. Scribe's cutting-edge technology and strong research backdrop present considerable competition, especially as the potential applications of CRISPR expand.